Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease.
Miao WangJing LiuBrandon K BellowsYue QiJiayi SunJun LiuAndrew E MoranDong ZhaoPublished in: Global heart (2020)
Implementing low central government prices will substantially improve the cost-effectiveness of statins for primary ASCVD prevention in 35-64-year-old Chinese adults.